Effects of a carbohydrate-reduced high-protein diet delivered with meal kits to Danish people with type 2 diabetes: protocol for a 12-month randomised controlled trial.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
13 Aug 2024
Historique:
medline: 15 8 2024
pubmed: 15 8 2024
entrez: 14 8 2024
Statut: epublish

Résumé

The cornerstone in the management of type 2 diabetes (T2D) is lifestyle modification including a healthy diet, typically one in which carbohydrate provides 45%-60% of total energy intake (E%). Nevertheless, systematic reviews and meta-analyses of trials with low carbohydrate diets (which are increased in protein and/or fat) for T2D have found improved glycaemic control in the first months relative to comparator diets with higher carbohydrate content. Studies lasting ≥1 year are inconclusive, which could be due to decreased long-term dietary adherence. We hypothesise that glucometabolic benefits can be achieved following 12 months of carbohydrate-restricted dieting, by maximising dietary adherence through delivery of meal kits, containing fresh, high-quality ingredients for breakfast, dinner and snacks, combined with nutrition education and counselling. This protocol describes a 12-month investigator-initiated randomised controlled, open-label, superiority trial with two parallel groups that will examine the effect of a carbohydrate-reduced high-protein (CRHP) diet compared with a conventional diabetes (CD) diet on glucometabolic control (change in glycated haemoglobin being the primary outcome) in 100 individuals with T2D and body mass index (BMI) >25 kg/m The trial has been approved by the National Committee on Health Research Ethics of the Capital Region of Denmark. The trial will be conducted in accordance with the Declaration of Helsinki. Results will be submitted for publication in international peer-reviewed scientific journals. NCT05330247. The trial protocol was approved on 9 March 2022 (study number: H-21057605). The latest version of the protocol, described in this manuscript, was approved on 23 June 2023.

Identifiants

pubmed: 39142677
pii: bmjopen-2024-084686
doi: 10.1136/bmjopen-2024-084686
doi:

Substances chimiques

Glycated Hemoglobin 0
Blood Glucose 0

Banques de données

ClinicalTrials.gov
['NCT05330247']

Types de publication

Journal Article Clinical Trial Protocol

Langues

eng

Sous-ensembles de citation

IM

Pagination

e084686

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Luise H P Kopp (LHP)

Department of Endocrinology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.

Christina M Søgaard-Hansen (CM)

Department of Endocrinology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.

Karen M Zachhau (KM)

Department of Endocrinology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.

Rasmus M Bastkjær (RM)

Department of Endocrinology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.

Barbara V Andersen (BV)

Department of Food Science, Aarhus University, Aarhus, Denmark.

Esben Budtz-Jørgensen (E)

Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark.

Derek V Byrne (DV)

Department of Food Science, Aarhus University, Aarhus, Denmark.

Nora Chaaban (N)

Department of Food Science, Aarhus University, Aarhus, Denmark.

Jens J Holst (JJ)

Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.

Trine B Klindt (TB)

Department of Endocrinology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.

Faidon Magkos (F)

Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.

Brice Ozenne (B)

Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
Neurobiology Research Unit and BrainDrugs, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.

Amirsalar Samkani (A)

Department of Endocrinology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.

Mads J Skytte (MJ)

Department of Endocrinology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.

Sten Madsbad (S)

Department of Endocrinology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Thure Krarup (T)

Department of Endocrinology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.
Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.

Mads N Thomsen (MN)

Department of Endocrinology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark mads.norvin.thomsen@regionh.dk.
Department of Endocrinology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH